Breaking Finance News

Horizon Pharma PLC (NASDAQ:HZNP) has been upgraded to Buy in a statement by Citigroup Inc. earlier today.

Citigroup Inc. has upgraded Horizon Pharma PLC (NASDAQ:HZNP) to Buy in a report released on 11/28/2016.

Previously on 1/19/2016, Jefferies & Co released a statement on Horizon Pharma PLC (NASDAQ:HZNP) upped the target price from $0.00 to $31.00 that suggested an upside of 0.69%.

Displaying a price of $21.56, Horizon Pharma PLC (NASDAQ:HZNP) traded 0.14% higher on the day. The last stock close price is up 16.40% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. The company has recorded a 50-day moving average of $18.68 and a 200-day moving average of $18.49. 594,539 shares of Horizon Pharma PLC traded, down from an average trading volume of 3,127,530

Performance Chart

Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma PLC has a with a one year low of $13.05 and a 52 week high of $23.44 Horizon Pharma PLC’s market capitalization is currently $0.

Also covering Horizon Pharma PLC's price target, a total of 13 equity analysts have released a ratings update on HZNP. The one year target is $30.23 with 4 brokers rating the stock a strong buy, 6 firms rating the stock a buy, 1 firm rating the stock a hold, one brokerage rating the company a underperform, and lastly zero brokerages rating the company a sell.

Brief Synopsis About Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units. Its segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. Its marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It also developed DUEXIS and RAYOS, known as LODOTRA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *